Sign in
Active, not recruitingPhase 3

A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops

Key facts

Who runs it
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
526 people enrolled
Started
13 May 2022
Ended
Dec 2025
Type of study
Interventional, 3 groups
Treatments tested
  • Lower dose atropine sulfate eye drops
  • Low dose atropine sulfate eye drops
  • placebo
Record updated
30 July 2025

Who can take part

Age
6 years to 10 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Child (female or male) aged 6 to 10 years
  • Myopia (SER of at least -0.50 D and no more myopic than -6.00 D) in each eye as measured by cycloplegic autorefraction
  • If present, astigmatism of ≤1.50 D in each eye as measured by cycloplegic autorefraction
  • Anisometropia SER of < 1.50 D as measured by cycloplegic autorefraction

Who cannot take part

  • Chronic use of any topical or systemic antimuscarinic/anticholinergic medications (e.g.,atropine, scopolamine, tropicamide) within 21 days prior to screening and/or anticipated need for chronic use during the study period (i.e., more than 7 consecutive days in 1 month or more than 30 total days in 1 year); Use of cycloplegic drops for dilated ocular exam was allowable
  • History of any disease or syndrome that predisposed the subject to severe myopia (e.g.,Marfan syndrome, Stickler syndrome, retinopathy of prematurity)
  • Heart rate persistently (for more than 10 minutes) > 120 beats per minute
  • Allergy to study drugs
  • History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus,spherophakia)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study was a randomized, double-blind, placebo-controlled, multicenter, superiority design, phase III clinical trial to compare the efficacy and safety of two low-concentration atropine sulfate eye drops versus placebo in delaying myopia progression in children.

The 3 groups in the trial

  • Experimental group 1Treatment being tested

    1 drop each time, once every night at bedtime

    Treatment: Lower dose atropine sulfate eye drops and Low dose atropine sulfate eye drops

  • Experimental group 2Treatment being tested

    1 drop each time, once every night at bedtime

    Treatment: Low dose atropine sulfate eye drops

  • control groupTreatment being tested

    1 drop each time, once every night at bedtime

    Treatment: placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops in Slowing the Progression of Myopia in Children
Record updated
30 July 2025